Vicore Pharma Holding AB (OSTO:VICO) Short Percentage of Float


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
28 GF Score
Price kr12.32
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:VICO vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Short Percentage of Float falls into.


OSTO:VICO
28GF Score
Vicore Pharma Holding AB OSTO:VICO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
28GF Score

Get the complete analysis for OSTO:VICO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.32
Price